Literature DB >> 2564593

Human monoclonal antibody to ganglioside GM2 for melanoma treatment.

R F Irie, T Matsuki, D L Morton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2564593     DOI： 10.1016/s0140-6736(89)92606-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

1.  Accelerated tumor growth mediated by sublytic levels of antibody-induced complement activation is associated with activation of the PI3K/AKT survival pathway.

Authors:  Xiaohong Wu; Govind Ragupathi; Katherine Panageas; Feng Hong; Philip O Livingston
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

2.  Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients.

Authors:  Kazuo Koyanagi; Christine Kuo; Taku Nakagawa; Takuji Mori; Hideaki Ueno; Arnulfo R Lorico; He-Jing Wang; Eddie Hseuh; Steven J O'Day; Dave S B Hoon
Journal:  Clin Chem       Date:  2005-04-07       Impact factor: 8.327

3.  Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions.

Authors:  Gianni Gerlini; Adrian Tun-Kyi; Christa Dudli; Günter Burg; Nicola Pimpinelli; Frank O Nestle
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

4.  Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

Authors:  H N Lode; T Moehler; R Xiang; A Jonczyk; S D Gillies; D A Cheresh; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

5.  The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value.

Authors:  Beatrix Kotlan; Gabriella Liszkay; Miri Blank; Orsolya Csuka; Timea Balatoni; Laszlo Toth; Klara Eles; Szabolcs Horvath; Gyorgy Naszados; Judit Olasz; Balazs Banky; Jozsef Toth; Maria Godeny; Francesco M Marincola; Miklos Kasler; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

6.  Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.

Authors:  S Ohta; A Honda; Y Tokutake; H Yoshida; N Hanai
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

7.  Antibodies to tumor necrosis factor: a component of B cell immune responses with a role in tumor/host interaction.

Authors:  J A Barbuto; W J Grimes; E M Hersh
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

8.  Chemical Synthesis of GM2 Glycans, Bioconjugation with Bacteriophage Qβ, and the Induction of Anticancer Antibodies.

Authors:  Zhaojun Yin; Steven Dulaney; Craig S McKay; Claire Baniel; Katarzyna Kaczanowska; Sherif Ramadan; M G Finn; Xuefei Huang
Journal:  Chembiochem       Date:  2015-12-04       Impact factor: 3.164

9.  Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides.

Authors:  S Zhang; F Helling; K O Lloyd; P O Livingston
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

10.  A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities.

Authors:  K Shitara; Y Kuwana; K Nakamura; Y Tokutake; S Ohta; H Miyaji; M Hasegawa; N Hanai
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.